CEL-SCI (CVM) Stock Price, News & Analysis

Company Overview

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Key Stats

• Today's Range: $9.12 to $9.86
• 50-Day Range: $2.29 to $9.52
• 52-Week Range: $1.98 to $39.30
• Volume: 152,267 shs
• Average Volume: 367,351 shs
• Market Capitalization: $65.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CEL-SCI Stock Analysis - MarketRank™

CEL-SCI scored higher than 29% of companies evaluated by MarketBeat, and ranked 822nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CEL-SCI.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CEL-SCI are expected to grow in the coming year, from ($0.29) to ($0.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CEL-SCI is -19.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CEL-SCI is -19.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CEL-SCI has a P/B Ratio of 63.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.25% of the float of CEL-SCI has been sold short.

Short Interest Ratio / Days to Cover

CEL-SCI has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CEL-SCI has recently decreased by 50.60%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CEL-SCI does not currently pay a dividend.

Dividend Growth

CEL-SCI does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.25% of the float of CEL-SCI has been sold short.

Short Interest Ratio / Days to Cover

CEL-SCI has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CEL-SCI has recently decreased by 50.60%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: N/A

News Sentiment

CEL-SCI has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for CEL-SCI this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for CVM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added CEL-SCI to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, CEL-SCI insiders have bought more of their company's stock than they have sold. Specifically, they have bought $219,995.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

14.06% of the stock of CEL-SCI is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.08% of the stock of CEL-SCI is held by institutions.

CVM Stock Analysis - Frequently Asked Questions

How have CVM shares performed this year?

CEL-SCI's stock was trading at $11.9970 at the beginning of 2025. Since then, CVM stock has decreased by 20.6% and is now trading at $9.52.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSE:CVM) posted its quarterly earnings results on Thursday, August, 15th. The company reported ($4.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.90) by $0.30.

When did CEL-SCI's stock split?

CEL-SCI's stock reverse split on Thursday, June 15th 2017.The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are CEL-SCI's major shareholders?

Top institutional shareholders of CEL-SCI include MAI Capital Management (0.94%), Bank of America Corp DE (0.60%), Geode Capital Management LLC (0.49%) and Group One Trading LLC. Insiders that own company stock include Geert R Kersten, Patricia B Prichep and Robert Eugene Watson.
View institutional ownership trends.

How do I buy shares of CEL-SCI?

Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CEL-SCI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CEL-SCI investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Pfizer (PFE), Canopy Growth (CGC) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 8/22/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CVM
• CIK: 725363
• Web: cel-sci.com
• Phone: 703-506-9460
• Fax: 703-506-9471
• Employees: 43
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($9.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -238.05%
• Return on Assets: -104.65%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 1.07
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 63.47

Miscellaneous

• Outstanding Shares: 6,882,000
• Free Float: 64,673,000
• Market Cap: $65.52 million
• Optionable: Optionable
• Beta: 0.52